• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中草药:全方位抗击 SARS-CoV-2 感染。

Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.

机构信息

Key Laboratory of Green Natural Products and Pharmaceutical Intermediates in Colleges and Universities of Shandong Province, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu, 273165, PR China; School of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, PR China.

School of Physics and Physical Engineering, Qufu Normal University, Qufu, 273165, PR China.

出版信息

J Ethnopharmacol. 2021 Apr 24;270:113869. doi: 10.1016/j.jep.2021.113869. Epub 2021 Jan 21.

DOI:10.1016/j.jep.2021.113869
PMID:33485973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7825841/
Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19), a highly pathogenic virus that has spread rapidly across the entire world. There is a critical need to develop safe and effective drugs, especially broad-spectrum antiviral and organ protection agents in order to treat and prevent this dangerous disease. It is possible that Chinese herbal medicine may play an essential role in the treatment of patients with SARS-CoV-2 infection.

AIM OF THE REVIEW

We aim to review the use of Chinese herbal medicine in the treatment of COVID-19 both in vitro and in clinical practice. Our goal was to provide a better understanding of the potential therapeutic effects of Chinese herbal medicine and to establish a "Chinese protocol" for the treatment of COVID-19.

MATERIALS AND METHODS

We systematically reviewed published research relating to traditional Chinese herbal medicines and the treatment of SARS-CoV-2 from inception to the 6 January 2021 by screening a range of digital databases (Web of Science, bioRxiv, medRxiv, China National Knowledge Infrastructure, X-MOL, Wanfang Data, Google Scholar, PubMed, Elsevier, and other resources) and public platforms relating to the management of clinical trials. We included the active ingredients of Chinese herbal medicines, monomer preparations, crude extracts, and formulas for the treatment of COVID-19.

RESULTS

In mainland China, a range of Chinese herbal medicines have been recognized as very promising anti-SARS-CoV-2 agents, including active ingredients (quercetagetin, osajin, tetrandrine, proscillaridin A, and dihydromyricetin), monomer preparations (xiyanping injection, matrine-sodium chloride injection, diammonium glycyrrhizinate enteric-coated capsules, and sodium aescinate injection), crude extracts (Scutellariae Radix extract and garlic essential oil), and formulas (Qingfei Paidu decoction, Lianhuaqingwen capsules, and Pudilan Xiaoyan oral liquid). All these agents have potential activity against SARS-CoV-2 and have attracted significant attention due to their activities both in vitro and in clinical practice.

CONCLUSIONS

As a key component of the COVID-19 treatment regimen, Chinese herbal medicines have played an irreplaceable role in the treatment of SARS-CoV-2 infection. The "Chinese protocol" has already demonstrated clear clinical importance. The use of Chinese herbal medicines that are capable of inhibiting SARS-Cov-2 infection may help to address this immediate unmet clinical need and may be attractive to other countries that are also seeking new options for effective COVID-19 treatment. Our analyses suggest that countries outside of China should also consider protocols involving Chinese herbal medicines combat this fast-spreading viral infection.

摘要

ETHNOPHARMACOLOGICAL 相关性:严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)感染会导致 2019 年冠状病毒病(COVID-19),这是一种高致病性病毒,已迅速在全球范围内传播。因此,开发安全有效的药物(尤其是广谱抗病毒和器官保护剂)来治疗和预防这种危险疾病至关重要。中草药在治疗 SARS-CoV-2 感染患者方面可能发挥重要作用。

目的

本综述旨在研究中草药在体外和临床实践中治疗 COVID-19 的应用。我们的目标是更好地了解中草药的潜在治疗效果,并为 COVID-19 的治疗建立一个“中国方案”。

材料和方法

我们通过筛选各种数字数据库(Web of Science、bioRxiv、medRxiv、中国国家知识基础设施、X-MOL、万方数据、谷歌学术、PubMed、Elsevier 以及其他与临床试验管理相关的资源)和公共平台,系统地回顾了从成立到 2021 年 1 月 6 日发表的有关传统中草药和 SARS-CoV-2 治疗的研究。我们纳入了中草药的活性成分、单体制剂、粗提取物和治疗 COVID-19 的配方。

结果

在中国内地,多种中草药被认为是非常有前途的抗 SARS-CoV-2 药物,包括活性成分(槲皮素、奥斯辛、汉防己甲素、普罗司卡林 A 和二氢杨梅素)、单体制剂(喜炎平注射液、苦参氯化钠注射液、甘草酸二铵肠溶胶囊和七叶皂苷钠注射液)、粗提取物(黄芩提取物和大蒜精油)和配方(清肺排毒汤、连花清瘟胶囊和蒲地蓝消炎口服液)。所有这些药物对 SARS-CoV-2 均具有潜在的活性,并且由于其在体外和临床实践中的活性而受到广泛关注。

结论

作为 COVID-19 治疗方案的重要组成部分,中草药在 SARS-CoV-2 感染的治疗中发挥了不可替代的作用。“中国方案”已经显示出明确的临床重要性。使用能够抑制 SARS-CoV-2 感染的中草药可能有助于解决这一紧迫的临床需求,并且可能对其他国家也具有吸引力,这些国家也在寻求有效的 COVID-19 治疗新选择。我们的分析表明,中国以外的国家也应考虑使用中草药来对抗这种快速传播的病毒感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/cb1abfffb5bb/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/905d9d6a865f/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/47f55557b52d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/61544e54648a/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/27ece3d7adf3/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/184ad232359f/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/7d3bbce1a7b4/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/a3ccaf04bb52/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/1e37138d9374/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/cb1abfffb5bb/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/905d9d6a865f/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/47f55557b52d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/61544e54648a/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/27ece3d7adf3/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/184ad232359f/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/7d3bbce1a7b4/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/a3ccaf04bb52/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/1e37138d9374/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ae/7825841/cb1abfffb5bb/gr8_lrg.jpg

相似文献

1
Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.中草药:全方位抗击 SARS-CoV-2 感染。
J Ethnopharmacol. 2021 Apr 24;270:113869. doi: 10.1016/j.jep.2021.113869. Epub 2021 Jan 21.
2
[Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus].[中草药及其活性成分干预人类冠状病毒的研究进展]
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1263-1271. doi: 10.19540/j.cnki.cjcmm.20200219.501.
3
An exhaustive comprehension of the role of herbal medicines in Pre- and Post-COVID manifestations.深入理解草药在新冠前后表现中的作用。
J Ethnopharmacol. 2022 Oct 5;296:115420. doi: 10.1016/j.jep.2022.115420. Epub 2022 May 30.
4
What can traditional plant therapy do in the face of Covid-19? Examples from traditional Chinese medicine.面对新冠疫情,传统植物疗法能做些什么?来自中医药的例子。
Afr Health Sci. 2023 Jun;23(2):56-66. doi: 10.4314/ahs.v23i2.7.
5
Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach.利用数据驱动的方法从中医药中寻找 COVID-19 的潜在治疗方法。
J Ethnopharmacol. 2020 Aug 10;258:112932. doi: 10.1016/j.jep.2020.112932. Epub 2020 May 4.
6
Traditional Chinese Medicine as the Preventive and Therapeutic Remedy for COVID-19.中医药防治新冠肺炎。
Curr Med Chem. 2024;31(21):3118-3131. doi: 10.2174/0929867330666230331084126.
7
[Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].[2019年冠状病毒病的中医临床研究方案分析]
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1232-1241. doi: 10.19540/j.cnki.cjcmm.20200220.501.
8
Prevention, treatment and potential mechanism of herbal medicine for Corona viruses: A review.草药防治冠状病毒及其潜在机制的研究进展。
Bioengineered. 2022 Mar;13(3):5480-5508. doi: 10.1080/21655979.2022.2036521.
9
Traditional Chinese medicine for treatment of novel infectious diseases: Current status and dilemma.中医药治疗新发传染病:现状与困境。
Biosci Trends. 2021 Sep 22;15(4):201-204. doi: 10.5582/bst.2021.01263. Epub 2021 Jul 1.
10
Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.中药麻杏石甘-苇茎汤治疗新型冠状病毒肺炎重型急性呼吸综合征患者的疗效:一项随机对照试验研究方案的结构化总结
Trials. 2020 Dec 23;21(1):1029. doi: 10.1186/s13063-020-04970-3.

引用本文的文献

1
Network Pharmacology and Experiment Verification-Based Strategy for Exploring the Mechanisms of Shuqing Granule in the Treatment of COVID-19.基于网络药理学和实验验证的疏清颗粒治疗新型冠状病毒肺炎作用机制探究策略
Pharmaceuticals (Basel). 2025 Aug 18;18(8):1216. doi: 10.3390/ph18081216.
2
Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024.变革者:2024年获美国食品药品监督管理局批准的重磅小分子药物
Pharmaceuticals (Basel). 2025 May 15;18(5):729. doi: 10.3390/ph18050729.
3
Identification and characterization of the TmSnRK2 family proteins related to chicoric acid biosynthesis in Taraxacum mongolicum.

本文引用的文献

1
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen.利用小分子体外重新利用筛选法鉴定严重急性呼吸综合征冠状病毒2 3C样蛋白酶(SARS-CoV-2 3CL-Pro)酶活性抑制剂
ACS Pharmacol Transl Sci. 2021 Mar 11;4(3):1096-1110. doi: 10.1021/acsptsci.0c00216. eCollection 2021 Jun 11.
2
Platycodin D, a natural component of Platycodon grandiflorum, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion.远志皂苷 D 是桔梗的一种天然成分,可通过阻碍膜融合来阻止溶酶体和 TMPRSS2 驱动的 SARS-CoV-2 感染。
Exp Mol Med. 2021 May;53(5):956-972. doi: 10.1038/s12276-021-00624-9. Epub 2021 May 25.
3
蒙古蒲公英中与菊苣酸生物合成相关的TmSnRK2家族蛋白的鉴定与特性分析
BMC Genomics. 2025 Mar 20;26(1):276. doi: 10.1186/s12864-025-11460-w.
4
Herbal Medicines as Complementary Therapy for Managing Complications in COVID-19 Patients with Diabetes Mellitus.草药作为管理2型糖尿病合并新冠患者并发症的辅助疗法
Diabetes Metab Syndr Obes. 2025 Jan 16;18:135-146. doi: 10.2147/DMSO.S498774. eCollection 2025.
5
The Impact of Traditional Chinese Herbal Decoctions Combined with Rehabilitation Therapy on Pulmonary Function and Respiratory Muscle Strength in COVID-19 Recovery Patients.中药汤剂联合康复治疗对新型冠状病毒肺炎康复患者肺功能及呼吸肌力量的影响
Infect Drug Resist. 2024 Oct 23;17:4617-4624. doi: 10.2147/IDR.S477984. eCollection 2024.
6
Cytokine Storm in COVID-19: Insight into Pathological Mechanisms and Therapeutic Benefits of Chinese Herbal Medicines.新型冠状病毒肺炎中的细胞因子风暴:中草药的病理机制及治疗作用洞察
Medicines (Basel). 2024 Jul 18;11(7):14. doi: 10.3390/medicines11070014.
7
Oral Bioavailability, Tissue Distribution, Metabolism, and Excretion of Panduratin A from Extract in Healthy Rats.从提取物中蓬莪术醇在健康大鼠体内的口服生物利用度、组织分布、代谢和排泄。
Drug Des Devel Ther. 2024 Jul 11;18:2905-2917. doi: 10.2147/DDDT.S453847. eCollection 2024.
8
Polyphenols as Therapeutics in Respiratory Diseases: Moving from Preclinical Evidence to Potential Clinical Applications.多酚类化合物作为呼吸系统疾病的治疗药物:从临床前证据到潜在的临床应用。
Int J Biol Sci. 2024 Jun 3;20(8):3236-3256. doi: 10.7150/ijbs.93875. eCollection 2024.
9
Anti-coronavirus and anti-pulmonary inflammation effects of iridoids, the common component from Chinese herbal medicines for the treatment of COVID-19.具有抗冠状病毒和抗炎作用的环烯醚萜类化合物是治疗 COVID-19 中草药的常见成分。
J Nat Med. 2024 Sep;78(4):1003-1012. doi: 10.1007/s11418-024-01820-3. Epub 2024 May 22.
10
The Role of Traditional Chinese Medicine and Chinese Pharmacopoeia in the Evaluation and Treatment of COVID-19.中医药和《中国药典》在评估和治疗 COVID-19 中的作用。
Curr Pharm Des. 2024;30(14):1060-1074. doi: 10.2174/0113816128217263240220060252.
Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease.
甘草酸通过抑制病毒主蛋白酶有效抑制 SARS-CoV-2 复制。
Viruses. 2021 Apr 2;13(4):609. doi: 10.3390/v13040609.
4
Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.连花清瘟胶囊治疗新型冠状病毒肺炎有效性和安全性的多中心前瞻性随机对照临床试验
Phytomedicine. 2021 May;85:153242. doi: 10.1016/j.phymed.2020.153242. Epub 2020 May 16.
5
Anti-SARS-CoV-2 Activity of Extract and Its Major Component Andrographolide in Human Lung Epithelial Cells and Cytotoxicity Evaluation in Major Organ Cell Representatives.提取物及其主要成分穿心莲内酯在人肺上皮细胞中的抗SARS-CoV-2活性以及主要器官细胞代表的细胞毒性评估
J Nat Prod. 2021 Apr 23;84(4):1261-1270. doi: 10.1021/acs.jnatprod.0c01324. Epub 2021 Apr 12.
6
The Scientific Foundation of Chinese Herbal Medicine against COVID-19.中药抗击新冠病毒的科学基础
Engineering (Beijing). 2020 Oct;6(10):1099-1107. doi: 10.1016/j.eng.2020.08.009. Epub 2020 Sep 5.
7
extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease .黄芩提取物和黄芩素抑制 SARS-CoV-2 及其 3CL 样蛋白酶的复制。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):497-503. doi: 10.1080/14756366.2021.1873977.
8
Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2.新型冠状病毒肺炎的药物可开发性:基于计算机模拟发现针对严重急性呼吸综合征冠状病毒2核衣壳(N)蛋白的潜在药物化合物
Genomics Inform. 2020 Dec;18(4):e43. doi: 10.5808/GI.2020.18.4.e43. Epub 2020 Dec 9.
9
SARS-CoV-2 Spike-Heat Shock Protein A5 (GRP78) Recognition may be Related to the Immersed Human Coronaviruses.严重急性呼吸综合征冠状病毒2刺突蛋白-热休克蛋白A5(葡萄糖调节蛋白78)识别可能与潜伏的人类冠状病毒有关。
Front Pharmacol. 2020 Dec 11;11:577467. doi: 10.3389/fphar.2020.577467. eCollection 2020.
10
Inhibitory effects of baicalein against herpes simplex virus type 1.黄芩素对1型单纯疱疹病毒的抑制作用。
Acta Pharm Sin B. 2020 Dec;10(12):2323-2338. doi: 10.1016/j.apsb.2020.06.008. Epub 2020 Jun 25.